CD200-AR-L

N/A

Report date: 2024/12/13 16:52:06

Base Information

Drug NameCD200-AR-L
Drug Alias NamehP-1-A-8CD200-AR-L
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD200 activation receptors agonists
TargetsCD200 activation receptors
Therapy Area/IndicationsDiffuse midline gliomaGlioblastomaGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MinnesotaOX2 Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesOX2 Therapeutics
Inactive CompaniesN/A
Active IndicationsDiffuse midline gliomaGlioblastomaGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A